PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17328768-7	2007	In addition, CB1 or CB2 antagonists (1 microM SR-141716A and SR-144528, respectively) blocked basal proliferation, suggesting that endogenous cannabinoids are implicated in neurosphere proliferation.	Rimonabant	46-56	cannabinoid receptor 2 (macrophage)	Mus musculus	20-23	
21922514-7	2012	Unexpectedly, SR141716A inhibited the expression of CB1R but increased the expression of CB2R in brains, spinal cords, and spleens simultaneously.	Rimonabant	14-23	cannabinoid receptor 2 (macrophage)	Mus musculus	89-93	
30300803-0	2018	Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.	Rimonabant	14-24	cannabinoid receptor 2 (macrophage)	Mus musculus	85-89	
33794254-6	2021	The effects of the CB1/CB2 receptor agonist HU210 were antagonized by the CB1 antagonist rimonabant, whereas the responses to the CB2 agonist JWH133 were blocked by the CB2 antagonist SR144528.	Rimonabant	89-99	cannabinoid receptor 2 (macrophage)	Mus musculus	23-26	
25281429-7	2015	Interestingly, transit was nearly normalized by coinjection of SR141716 and AM630 (CB1R and CB2R antagonist, respectively), and AM630 also reduced the delay of plasma glucose appearance induced by anandamide.	Rimonabant	63-71	cannabinoid receptor 2 (macrophage)	Mus musculus	92-96